{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:24:50Z","timestamp":1791645890611,"version":"4.3.4"},"reference-count":143,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Described as early as Hippocrates in his \u201cThird Book of Endemic Diseases,\u201d Beh\u00e7et's Disease (BD), also known as \u201cThe Silk Road Disease\u201d following its initial demographics, consists of a triad of recurrent oro-genital ulcers and associated uveitis. Current demographics and rising percentages of patients seen far beyond the Silk Road in Ocular Inflammatory Disease and Uveitis Clinics list BD uveitis as one of the frontliners of non-infectious autoinflammatory eye diseases. Clinical features of BD and juvenile-onset BD are detailed alongside various approaches in classification and suggested algorithms for diagnosis that are outlined in this review. With the ongoing Human Microbiome Project and studies such as the MAMBA study, the role of the human microbiome in BD is highlighted in the pathophysiology of BD to include the current research and literature perspective. Furthermore, with the advancement of recent diagnostic and investigative techniques, especially in the field of Optical Coherence Tomography (OCT), disease-related characteristics are updated to encompass SD, EDI and OCT-angiography characteristics of BD. Having entered the era of biologic therapy, the role of various specific cytokine-blocking biologic drugs, such as TNF-\u03b1 inhibitors (e.g., adalimumab, infliximab), interferon \u03b1-2a inhibitors, IL-6 and IL-1 inhibitors are presented and contrasted alongside the conventional immunosuppressant drugs and the classic old gold standard: corticosteroids (systemic or local). Finally, with the ongoing SARS-CoV-2 pandemic, it was not possible to conclude the review without reviewing the latest evidence-based literature reporting BD morbidity in this era, the observed pattern and treatment recommendations as well as those related to reported post-vaccine complications and emergence of BD.<\/jats:p>","DOI":"10.3389\/fmed.2022.968345","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T07:19:14Z","timestamp":1662535154000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Beh\u00e7et uveitis: Current practice and future perspectives"],"prefix":"10.3389","volume":"9","author":[{"given":"Shereen H.","family":"Aboul Naga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lameece Moustafa","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radwa T.","family":"El Zanaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Refaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana H.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaafar","family":"Ragab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"key":"B1","first-page":"687","article-title":"Hippocrates and rheumatology","volume":"22","author":"Pasero","year":"2004","journal-title":"Clin Exp Rheumatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/bjo.40.6.355","article-title":"Description of Beh\u00e7et's syndrome in the Hippocratic third book of endemic diseases","volume":"40","author":"Feigenbaum","year":"1956","journal-title":"Br J Ophthalmol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2160610","DOI":"10.1155\/2017\/2160610","article-title":"Knitting the threads of silk through time: Beh\u00e7et's disease-past, present, and future","volume":"2017","author":"Adeeb","year":"2017","journal-title":"Int J Rheumatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5152\/eurjrheum.2019.19121","article-title":"Pediatric Beh\u00e7et's disease - clinical aspects and current concepts","volume":"7","author":"Yildiz","year":"2019","journal-title":"Eur J Rheumatol."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-022-03038-1","article-title":"Development and implementation of the AIDA International Registry for patients with Beh\u00e7et's disease","author":"Vitale","year":"2022","journal-title":"Intern Emerg Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1080\/09273948.2020.1714060","article-title":"Patterns of uveitis in Egypt","volume":"29","author":"Abdelwareth Mohammed","year":"2020","journal-title":"Ocul Immunol Inflamm."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s10067-020-05362-3","article-title":"Characteristics, evolution, and outcome of patients with non-infectious uveitis referred for rheumatologic assessment and management: an Egyptian multicenter retrospective study","volume":"40","author":"Hassan","year":"2021","journal-title":"Clin Rheumatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1186\/s13063-020-04444-6","article-title":"Modulation of gut microbiota through nutritional interventions in Beh\u00e7et's syndrome patients (the MAMBA study): study protocol for a randomized controlled trial","volume":"21","author":"Pagliai","year":"2020","journal-title":"Trials."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41927-020-00172-1","article-title":"Diagnosis of Beh\u00e7et's disease: clinical characteristics, diagnostic criteria, and differential diagnoses","volume":"5","author":"Kiafar","year":"2021","journal-title":"BMC Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/rheumatology\/kew486","article-title":"Exploring the variability in Beh\u00e7et's disease prevalence: a meta-analytical approach","volume":"57","author":"Maldini","year":"2017","journal-title":"Rheumatology."},{"key":"B11","first-page":"3","article-title":"One year in review 2020: Beh\u00e7et's syndrome","volume":"38","author":"Hatemi","year":"2020","journal-title":"Clin Exp Rheumatol."},{"key":"B12","first-page":"1078","article-title":"International Study Group for Beh\u00e7et's Disease","volume":"335","year":"1990","journal-title":"Lancet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et's syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The International Criteria for Beh\u00e7et's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"607725","DOI":"10.3389\/fmed.2020.607725","article-title":"JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis","volume":"7","author":"Moura","year":"2021","journal-title":"Front Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/j.ophtha.2018.05.014","article-title":"Targeting interleukin-23 in the treatment of noninfectious uveitis","volume":"125","author":"Pepple","year":"2018","journal-title":"Ophthalmology."},{"key":"B17","unstructured":"Hmpdacc.org.2022"},{"key":"B18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00296-018-4208-9","article-title":"Diagnostic\/classification criteria in pediatric Beh\u00e7et's disease","volume":"39","author":"Batu","year":"2019","journal-title":"Rheumatol Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3349\/ymj.1997.38.6.365","article-title":"Diagnostic criteria of Beh\u00e7et's disease: problems and suggestions","volume":"38","author":"Lee","year":"1997","journal-title":"Yonsei Med J."},{"key":"B20","first-page":"S45","article-title":"A reassessment of the International Study Group criteria for the diagnosis (classification) of Beh\u00e7et's syndrome","volume":"19","author":"Tun\u00e7","year":"2001","journal-title":"Clin Exp Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.4103\/injr.injr_29_17","article-title":"Performance of classification criteria for Behcet's disease in an Egyptian cohort","volume":"12","author":"Hussein","year":"2017","journal-title":"Indian J Rheumatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/acr.22671","article-title":"Distinctions between diagnostic and classification criteria: comment on the article by Aggarwal et al","volume":"68","author":"Taylor","year":"2016","journal-title":"Arthritis Care Res."},{"key":"B23","first-page":"291","article-title":"Beh\u00e7et's Disease Research Committee of Japan. Beh\u00e7et's disease: Guide to diagnosis of Beh\u00e7et's disease","volume":"18","author":"O'Neill","year":"1974","journal-title":"Jpn J Opthaimol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2169\/internalmedicine.2035-18","article-title":"Clinical and genetic aspects of Beh\u00e7et's disease in Japan","volume":"58","author":"Kirino","year":"2019","journal-title":"Intern Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/MD.0b013e318211bf28","article-title":"Beh\u00e7et disease: evolution of clinical manifestations","volume":"90","author":"Ideguchi","year":"2011","journal-title":"Medicine."},{"key":"B26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s13075-016-1115-x","article-title":"Continuous evolution of clinical phenotype in 578 Japanese patients with Beh\u00e7et's disease: a retrospective observational study","volume":"18","author":"Kirino","year":"2016","journal-title":"Arthritis Res Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.ophtha.2003.07.018","article-title":"Comparison of patients with Beh\u00e7et's disease in the 1980s and (990s","volume":"111","author":"Yoshida","year":"2004","journal-title":"Ophthalmology."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/09273948.2017.1279840","article-title":"Beh\u00e7et uveitis","volume":"25","author":"Cunningham","year":"2017","journal-title":"Ocul Immunol Inflamm."},{"key":"B29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4103\/0974-9233.58425","article-title":"Beh\u00e7et's uveitis","volume":"16","author":"Tugal-Tutkun","year":"2009","journal-title":"Middle East Afr J Ophthalmol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","article-title":"Beh\u00e7et's disease","volume":"341","author":"Sakane","year":"1999","journal-title":"N Engl J Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","article-title":"Uveitis in Beh\u00e7et disease: an analysis of 880 patients","volume":"138","author":"Tugal-Tutkun","year":"2004","journal-title":"Am J Ophthalmol."},{"key":"B32","first-page":"86","article-title":"Beh\u00e7et's syndrome and ocular involvement: changes over time","volume":"38","author":"Posarelli","year":"2020","journal-title":"Clin Exp Rheumatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.15570\/actaapa.2018.37","article-title":"Relationship between age at onset and clinical characteristics of Beh\u00e7et's disease","volume":"27","author":"Ghembaza","year":"2018","journal-title":"Acta Dermatovenerol Alpina Pannonica Adriatica."},{"key":"B34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajo.2021.03.058","article-title":"Classification criteria for Beh\u00e7et disease uveitis","volume":"228","year":"2021","journal-title":"Am J Ophthalmol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"169","DOI":"10.4274\/tjo.galenos.2019.60308","article-title":"Beh\u00e7et's uveitis: current diagnostic and therapeutic approach","volume":"50","author":"\u00c7akar \u00d6zdal","year":"2020","journal-title":"Turkish J Ophthalmol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s10384-005-0307-8","article-title":"Neovascularization of the optic disc in Beh\u00e7et's disease","volume":"50","author":"Tugal-Tutkun","year":"2006","journal-title":"Jpn J Ophthalmol."},{"key":"B37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-81-322-2295-8_3","article-title":"Beh\u00e7et Disease","volume-title":"Uveitis: An Update.","author":"Onal","year":"2016"},{"key":"B38","article-title":"Vitrectomy for macular hole in Behcet's Disease","author":"Macky","year":"2016","journal-title":"Conference Paper of American Society of Retina Specialist at San Francisco"},{"key":"B39","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4274\/tjo.77632","article-title":"Vitreomacular interface disorders in Beh\u00e7et's uveitis","volume":"47","author":"Eser \u00d6zt\u00fcrk","year":"2017","journal-title":"Turkish J Ophthalmol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1177\/112067210201200514","article-title":"Posterior segment involvement in ocular Beh\u00e7et's disease","volume":"12","author":"Ozdal","year":"2002","journal-title":"Eur J Ophthalmol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1080\/09273948.2020.1736310","article-title":"An algorithm for the diagnosis of Beh\u00e7et disease uveitis in adults","volume":"29","author":"Tugal-Tutkun","year":"2020","journal-title":"Ocular Immunol Inflamm."},{"key":"B42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/widm.8","article-title":"Classification and regression trees","volume":"1","author":"Loh","year":"2011","journal-title":"WIREs Data Min Knowl Discov."},{"key":"B43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12969-016-0070-z","article-title":"Beh\u00e7et's disease in children, an overview","volume":"14","author":"Kon\u00e9-Paut","year":"2016","journal-title":"Pediatr Rheumatol Online J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2147\/TCRM.S232660","article-title":"Beh\u00e7et's disease in children: diagnostic and management challenges","volume":"16","author":"Costagliola","year":"2020","journal-title":"Ther Clin Risk Manag."},{"key":"B45","doi-asserted-by":"publisher","first-page":"627192","DOI":"10.3389\/fmed.2021.627192","article-title":"Pediatric Beh\u00e7et's disease","volume":"8","author":"Yildiz","year":"2021","journal-title":"Front Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1136\/annrheumdis-2015-208491","article-title":"Consensus classification criteria for paediatric Beh\u00e7et's disease from a prospective observational cohort: PEDBD","volume":"75","author":"Kon\u00e9-Paut","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jaapos.2009.04.016","article-title":"Ocular findings in childhood-onset Beh\u00e7et disease","volume":"13","author":"Citirik","year":"2009","journal-title":"J Am Assoc Pediatr Ophthalmol Strabismus."},{"key":"B48","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jaad.2007.10.452","article-title":"Demographic and clinical properties of juvenile-onset Beh\u00e7et's disease: a controlled multicenter study","volume":"58","author":"Karincaoglu","year":"2008","journal-title":"J Am Acad Dermatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s11739-021-02725-9","article-title":"Clinical profile and evolution of patients with juvenile-onset Beh\u00e7et's syndrome over a 25-year period: insights from the AIDA network","volume":"16","author":"Sota","year":"2021","journal-title":"Intern Emerg Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3109\/09273948.2011.555592","article-title":"Beh\u00e7et disease in children","volume":"19","author":"Atmaca","year":"2011","journal-title":"Ocular Immunol Inflamm."},{"key":"B51","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/rheumatology\/38.5.457","article-title":"Childhood Beh\u00e7et's disease: clinical features and comparison with adult-onset disease","volume":"38","author":"Krause","year":"1999","journal-title":"Rheumatology."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/S0002-9394(03)00791-8","article-title":"Childhood-onset uveitis in Beh\u00e7et disease:a descriptive study of 36 cases","volume":"136","author":"Tugal-Tutkun","year":"2003","journal-title":"Am J Ophthalmol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/09273948.2016.1205100","article-title":"Review for diagnostics of the year: multimodal imaging in Beh\u00e7et uveitis","volume":"25","author":"Tugal-Tutkun","year":"2017","journal-title":"Ocul Immunol Inflamm."},{"key":"B54","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/09273948.2013.795228","article-title":"Differential diagnosis of Beh\u00e7et uveitis","volume":"21","author":"Tugal-Tutkun","year":"2013","journal-title":"Ocul Immunol Inflamm."},{"key":"B55","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/IIO.0b013e318265d56a","article-title":"Imaging in the diagnosis and management of Beh\u00e7et disease","volume":"52","author":"Tugal-Tutkun","year":"2012","journal-title":"Int Ophthalmol Clin."},{"key":"B56","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/09273940490518757","article-title":"Indocyanine green and fundus fluorescein angiographic findings in patients with active ocular Beh\u00e7et's disease","volume":"13","author":"Gedik","year":"2005","journal-title":"Ocul Immunol Inflamm."},{"key":"B57","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/00006982-200003000-00018","article-title":"Indocyanine green angiography in Beh\u00e7et's uveitis","volume":"20","author":"Klaeger","year":"2000","journal-title":"Retina."},{"key":"B58","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ejr.2020.05.001","article-title":"Fundus fluorescein angiography and optical coherence tomography findings in ocular and non-ocular Beh\u00e7et's disease","volume":"42","author":"Mamdouh","year":"2020","journal-title":"Egyptian Rheumatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1097\/IAE.0000000000000197","article-title":"Use of ultra-wide-field retinal imaging in the management of active Beh\u00e7et retinal vasculitis","volume":"34","author":"Mesquida","year":"2014","journal-title":"Retina."},{"key":"B60","doi-asserted-by":"publisher","first-page":"219","DOI":"10.5935\/0004-2749.20140056","article-title":"Inner and outer segment junction (IS\/OS line) integrity in ocular Beh\u00e7et's disease","volume":"77","author":"Y\u00fcksel","year":"2014","journal-title":"Arquivos Brasileiros Oftalmologia."},{"key":"B61","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.ajo.2014.11.029","article-title":"Nonglaucomatous localized retinal nerve fiber layer defects in Beh\u00e7et uveitis","volume":"159","author":"Oray","year":"2015","journal-title":"Am J Ophthalmol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/j.ophtha.2014.03.006","article-title":"Objective measurement of vitreous inflammation using optical coherence tomography","volume":"121","author":"Keane","year":"2014","journal-title":"Ophthalmology."},{"key":"B63","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1167\/tvst.4.5.4","article-title":"Automated analysis of vitreous inflammation using spectral-domain optical coherence tomography","volume":"4","author":"Keane","year":"2015","journal-title":"Transl Vis Sci Technol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"6033","DOI":"10.1167\/iovs.13-12231","article-title":"Choroidal thickness in Beh\u00e7et's uveitis: an enhanced depth imaging-optical coherence tomography and its association with angiographic changes","volume":"54","author":"Kim","year":"2013","journal-title":"Investig Ophthalmol Vis Sci."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1136\/bjophthalmol-2014-305333","article-title":"Changes in subfoveal choroidal thickness associated with uveitis activity in patients with Beh\u00e7et's disease","volume":"98","author":"Ishikawa","year":"2014","journal-title":"Br J Ophthalmol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1167\/iovs.10-6282","article-title":"Three-dimensional visualization of ocular vascular pathology by optical coherence angiography in vivo","volume":"52","author":"Miura","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1097\/IAE.0000000000001418","article-title":"Optical coherence tomography angiography in patients with Beh\u00e7et uveitis","volume":"37","author":"Khairallah","year":"2017","journal-title":"Retina."},{"key":"B68","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1007\/s10792-021-01968-x","article-title":"Post-remission retinal microvascular and choroidal thickness changes in eyes with Beh\u00e7et's disease posterior uveitis: an OCTA longitudinal study","volume":"41","author":"Wassef","year":"2021","journal-title":"Int Ophthalmol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2180723","DOI":"10.1155\/2017\/2180723","article-title":"Assessment of vascular change using swept-source optical coherence tomography angiography: a new theory explains central visual loss in Beh\u00e7et's disease","volume":"2017","author":"Somkijrungroj","year":"2017","journal-title":"J Ophthalmol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/09273948.2019.1612452","article-title":"Optical coherence tomography angiography findings in active and inactive ocular Beh\u00e7et disease","volume":"28","author":"Accorinti","year":"2020","journal-title":"Ocul Immunol Inflamm."},{"key":"B71","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1364\/BOE.390430","article-title":"High-resolution wide-field OCT angiography with a self-navigation method to correct microsaccades and blinks","volume":"11","author":"Wei","year":"2020","journal-title":"Biomed Opt Express."},{"key":"B72","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13023-017-0681-6","article-title":"An update on the use of biologic therapies in the management of uveitis in Beh\u00e7et's disease: a comprehensive review","volume":"12","author":"McNally","year":"2017","journal-title":"Orphanet J Rare Dis."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1136\/ard.2007.080432","article-title":"EULAR recommendations for the management of Beh\u00e7et disease","volume":"67","author":"Hatemi","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"B74","first-page":"632","article-title":"Adamantiades-Beh\u00e7et disease","volume-title":"Diagnosis Treatment of Uveitis.","author":"Zafirakis","year":"2002"},{"key":"B75","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000490674","article-title":"Efficacy of dexamethasone implants in uveitic macular edema in cases with Beh\u00e7et disease","volume":"241","author":"Yalcinbayir","year":"2019","journal-title":"Ophthalmologica."},{"key":"B76","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3109\/09273948.2015.1042167","article-title":"Intravitreal dexamethasone implant for treatment of refractory Beh\u00e7et posterior uveitis: one-year follow-up results","volume":"23","author":"Co\u015fkun","year":"2015","journal-title":"Ocul Immunol Inflamm."},{"key":"B77","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/978-3-319-09126-6_46","article-title":"Surgical therapy: dexamethasone biodegradable intravitreal implant (Ozurdex\u00ae)","volume-title":"Uveitis: A Practical Guide to the Diagnosis Treatment of Intraocular Inflammation.","author":"Wang","year":"2017"},{"key":"B78","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/ICU.0b013e32834bbe91","article-title":"Ocular Beh\u00e7et disease: current therapeutic approaches","volume":"22","author":"Evereklioglu","year":"2011","journal-title":"Curr Opin Ophthalmol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3109\/08820538.2011.588665","article-title":"The use of biologic agents in the treatment of ocular manifestations of Beh\u00e7et's disease","volume":"26","author":"Benitah","year":"2011","journal-title":"Semin Ophthalmol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/acr.20308","article-title":"Azathioprine in severe uveitis of Beh\u00e7et's disease","volume":"62","author":"Saadoun","year":"2010","journal-title":"Arthritis Care Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":"A controlled trial of azathioprine in Beh\u00e7et's syndrome","volume":"322","author":"Yazici","year":"1990","journal-title":"N Engl J Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/art.1780400425","article-title":"Azathioprine in Beh\u00e7et's syndrome: effects on long-term prognosis","volume":"40","author":"Hamuryudan","year":"1997","journal-title":"Arthritis Rheum."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","article-title":"Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Beh\u00e7et's disease","volume":"1","author":"Masuda","year":"1989","journal-title":"Lancet."},{"key":"B84","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1136\/bjo.76.4.241","article-title":"Low dose cyclosporin A versus pulsed cyclophosphamide in Beh\u00e7et's syndrome: a single masked trial","volume":"76","author":"Ozyazgan","year":"1992","journal-title":"Br J Ophthalmol."},{"key":"B85","first-page":"S84","article-title":"Cyclosporine for Beh\u00e7et's uveitis: is it associated with an increased risk of neurological involvement?","volume":"26","author":"Akman-Demir","year":"2008","journal-title":"Clin Exp Rheumatol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1046\/j.1442-9071.2001.00445.x","article-title":"Central nervous system symptoms in a population of Beh\u00e7et's disease patients with refractory uveitis treated with cyclosporine A","volume":"29","author":"Kato","year":"2001","journal-title":"Clin Exp Ophthalmol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e5516","DOI":"10.1097\/MD.0000000000005516","article-title":"Cytotoxic Th1 and Th17 cells infiltrate the intestinal mucosa of Beh\u00e7et patients and exhibit high levels of TNF-\u03b1 in early phases of the disease","volume":"95","author":"Emmi","year":"2016","journal-title":"Medicine."},{"key":"B88","first-page":"S24","article-title":"Natural killer cells dominate a Th-1 polarized response in Beh\u00e7et's disease patients with uveitis","volume":"33","author":"Kucuksezer","year":"2015","journal-title":"Clin Exp Rheumatol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.3390\/ijms21093072","article-title":"Beh\u00e7et's disease, and the role of TNF-\u03b1 and TNF-\u03b1 blockers","volume":"21","author":"van der Houwen","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B90","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1755-3768.2011.02348.x","article-title":"Light on the horizont: biologicals in Beh\u00e7et uveitis","volume":"91","author":"Hazirolan","year":"2013","journal-title":"Acta Ophthalmol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Ophthalmology."},{"key":"B92","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.survophthal.2015.06.004","article-title":"Anti-tumor necrosis factor-\u03b1 therapy in uveitis","volume":"60","author":"Cordero-Coma","year":"2015","journal-title":"Survey Ophthalmol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet."},{"key":"B95","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10067-016-3480-x","article-title":"Efficacy and safety of adalimumab in Beh\u00e7et's disease-related uveitis: a multicenter retrospective observational study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin Rheumatol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/bjophthalmol-2017-310733","article-title":"Cumulative retention rate of adalimumab in patients with Beh\u00e7et's disease-related uveitis: a four-year follow-up study","volume":"102","author":"Fabiani","year":"2018","journal-title":"Br J Ophthalmol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00296-018-4193-z","article-title":"Efficacy and safety of biological therapy compared to synthetic immunomodulatory drugs or placebo in the treatment of Beh\u00e7et's disease associated uveitis: a systematic review","volume":"39","author":"Urruticoechea-Arana","year":"2019","journal-title":"Rheumatol Int."},{"key":"B98","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12969-019-0333-6","article-title":"Early administration of adalimumab for paediatric uveitis due to Beh\u00e7et's disease","volume":"17","author":"Hiyama","year":"2019","journal-title":"Pediatr Rheumatol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273948.2021.1900276.","article-title":"Efficacy of biosimilar adalimumab in the treatment of Beh\u00e7et's uveitis","author":"Soheilian","year":"2021","journal-title":"Ocul Immunol Inflamm."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s40123-021-00387-6","article-title":"Role of adalimumab biosimilar in the treatment of non-anterior uveitis associated with Beh\u00e7et's syndrome","volume":"10","author":"Sota","year":"2021","journal-title":"Ophthalmol Ther."},{"key":"B101","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/APO.0000000000000380","article-title":"Effectiveness of SB5, an adalimumab biosimilar, in patients with noninfectious uveitis: a real-life monocentric experience","volume":"10","author":"Sota","year":"2021","journal-title":"Asia Pac J Ophthalmol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00296-008-0606-8","article-title":"Safety and efficacy of infliximab therapy in active Beh\u00e7et's uveitis: an open-label trial","volume":"29","author":"Al-Rayes","year":"2008","journal-title":"Rheumatol Int."},{"key":"B103","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ajo.2008.09.010","article-title":"Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Beh\u00e7et disease","volume":"146","author":"Tabbara","year":"2008","journal-title":"Am J Ophthalmol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/bjo.2009.158840","article-title":"Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Beh\u00e7et disease","volume":"94","author":"Yamada","year":"2010","journal-title":"Br J Ophthalmol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/eye.2014.138","article-title":"Long-term efficacy of infliximab on background vascular leakage in patients with Beh\u00e7et's disease","volume":"28","author":"Keino","year":"2014","journal-title":"Eye."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.ophtha.2014.04.042","article-title":"Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Beh\u00e7et's disease: a multicenter study","volume":"121","author":"Takeuchi","year":"2014","journal-title":"Ophthalmology."},{"key":"B107","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/rheumatology\/keq366","article-title":"A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Beh\u00e7et's disease: a comparative 4-week study","volume":"50","author":"Markomichelakis","year":"2011","journal-title":"Rheumatology."},{"key":"B108","first-page":"86","article-title":"Infliximab for uveitis of Beh\u00e7et's syndrome: a trend for earlier initiation","volume":"35","author":"Guzelant","year":"2017","journal-title":"Clin Exp Rheumatol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/art.39667","article-title":"Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the french uveitis network","volume":"68","author":"Vallet","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1002\/art.41026","article-title":"Comparative study of infliximab versus adalimumab in refractory uveitis due to Beh\u00e7et's disease: national multicenter study of 177 cases","volume":"71","author":"Atienza-Mateo","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5152\/eurjrheum.2017.16112","article-title":"Rapid loss of efficacy of biosimilar infliximab in three patients with Beh\u00e7et's disease after switching from infliximab originator","volume":"4","author":"Cantini","year":"2017","journal-title":"Eur J Rheumatol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/rheumatology\/kez063.033","article-title":"Biosimilar infliximab for Beh\u00e7et's syndrome: a case series","volume":"121","author":"Dincses","year":"2019","journal-title":"Clin Exp Rheumatol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3109\/09273948.2012.741744","article-title":"Beh\u00e7et disease-associated uveitis successfully treated with golimumab","volume":"21","author":"Mesquida","year":"2013","journal-title":"Ocul Immunol Inflamm."},{"key":"B114","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/09273948.2017.1351573","article-title":"Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with Beh\u00e7et's disease","volume":"27","author":"Fabiani","year":"2019","journal-title":"Ocul Immunol Inflamm."},{"key":"B115","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3109\/09273948.2015.1133835","article-title":"Interferon alpha-2a therapy in patients with refractory Beh\u00e7et uveitis","volume":"25","author":"Hasanreisoglu","year":"2017","journal-title":"Ocul Immunol Inflamm."},{"key":"B116","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/09273948.2016.1206204","article-title":"Long-term efficacy of interferon in severe uveitis associated with Beh\u00e7et disease","volume":"25","author":"Diwo","year":"2017","journal-title":"Ocul Immunol Inflamm."},{"key":"B117","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/09273948.2017.1332768","article-title":"Long-term efficacy of pegylated interferon alpha-2b in Beh\u00e7et's uveitis: a small case series","volume":"27","author":"Celiker","year":"2019","journal-title":"Ocul Immunol Inflamm."},{"key":"B118","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3109\/09273948.2015.1010652","article-title":"Potential of pegylated interferon alpha-2a in Beh\u00e7et uveitis: a report of five cases","volume":"24","author":"Bielefeld","year":"2016","journal-title":"Ocul Immunol Inflamm."},{"key":"B119","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/archophthalmol.2011.3","article-title":"Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Beh\u00e7et uveitis","volume":"129","author":"Onal","year":"2011","journal-title":"Arch Ophthalmol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/09273948.2017.1355471","article-title":"Tocilizumab for the treatment of Beh\u00e7et uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy","volume":"26","author":"Eser Ozturk","year":"2018","journal-title":"Ocul Immunol Inflamm."},{"key":"B121","first-page":"S34","article-title":"The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Beh\u00e7et's disease: results of a multicentre open-label study","volume":"34","author":"Santos-G\u00f3mez","year":"2016","journal-title":"Clin Exp Rheumatol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.sjopt.2016.12.004","article-title":"Successful treatment of Beh\u00e7et's uveitis with Tocilizumab","volume":"31","author":"Alokaily","year":"2017","journal-title":"Saudi J Ophthalmol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/rheumatology\/kex480","article-title":"Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Beh\u00e7et's disease: multicentre retrospective study","volume":"57","author":"Atienza-Mateo","year":"2018","journal-title":"Rheumatology."},{"key":"B124","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.semarthrit.2015.11.012","article-title":"Tocilizumab in severe and refractory Beh\u00e7et's disease: Four cases and literature review","volume":"45","author":"Deroux","year":"2016","journal-title":"Semin Arthr Rheumat."},{"key":"B125","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ajo.2017.08.019","article-title":"Primary (Month-6) outcomes of the STOP-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis","volume":"183","author":"Sepah","year":"2017","journal-title":"Am J Ophthalmol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ophtha.2018.09.044","article-title":"Efficacy and safety of sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU): the phase 2 SATURN study","volume":"126","author":"Heissigerov\u00e1","year":"2019","journal-title":"Ophthalmology."},{"key":"B127","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1007\/s10067-016-3527-z","article-title":"The emerging role of interleukin (IL)-1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin Rheumatol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","article-title":"Interleukin (IL)-1 inhibition with anakinra and canakinumab in Beh\u00e7et's disease-related uveitis: a multicenter retrospective observational study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin Rheumatol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/09273948.2018.1511810","article-title":"The presence of uveitis is associated with a sustained response to the interleukin (IL)-1 inhibitors anakinra and canakinumab in Beh\u00e7et's disease","volume":"28","author":"Fabiani","year":"2020","journal-title":"Ocul Immunol Inflamm."},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1177\/20587384211006584","article-title":"Off-label use of anti-IL-1 drugs in rheumatic diseases","volume":"35","author":"Stefania","year":"2021","journal-title":"Int J Immunopathol Pharmacol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"2324400","DOI":"10.1155\/2021\/2324400","article-title":"Role of Janus Kinase (JAK) inhibitor in autoimmune ocular inflammation: a systematic review","volume":"2021","author":"Wen","year":"2021","journal-title":"J Immunol Res."},{"key":"B132","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1055\/a-1741-8104","article-title":"Janus kinase inhibitors: next-generation treatment for uveitis","volume":"239","author":"El-Shabrawi","year":"2022","journal-title":"Klin Monbl Augenheilkd."},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219810.","article-title":"Correspondence on \u2018A pilot study of tofacitinib for refractory Beh\u00e7et's syndrome\u2019","author":"Zou","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B134","doi-asserted-by":"publisher","first-page":"e665","DOI":"10.1111\/aos.13699","article-title":"Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis \u2013 a systematic review","volume":"96","author":"Leal","year":"2018","journal-title":"Acta Ophthalmol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1089\/jop.2011.0199","article-title":"Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis","volume":"28","author":"Farvardin","year":"2012","journal-title":"J Ocular Pharmacol Ther."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.ophtha.2009.12.011","article-title":"Intravitreal adalimumab for refractory uveitis-related macular edema","volume":"117","author":"Androudi","year":"2010","journal-title":"Ophthalmology."},{"key":"B137","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3109\/09273948.2014.990041","article-title":"Intravitreal adalimumab in active noninfectious uveitis: a pilot study","volume":"24","author":"Hamam","year":"2016","journal-title":"Ocul Immunol Inflamm."},{"key":"B138","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1097\/IAE.0000000000001109","article-title":"Intravitreal infliximab in refractory uveitis in Beh\u00e7et's disease: a safety and efficacy clinical study","volume":"36","author":"Hamza","year":"2016","journal-title":"Retina."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1097\/IAE.0000000000003095","article-title":"Monthly intravitreal infliximab in Beh\u00e7et's disease active posterior uveitis: a long-term safety study","volume":"41","author":"Refaat","year":"2020","journal-title":"Retina."},{"key":"B140","doi-asserted-by":"publisher","first-page":"e14507","DOI":"10.1111\/dth.14507","article-title":"Treatment considerations for Beh\u00e7et disease in the era of COVID-19: a narrative review","volume":"34","author":"Elmas \u00d6","year":"2021","journal-title":"Dermatol Ther."},{"key":"B141","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/mr\/roab016","article-title":"COVID-19 in patients with Beh\u00e7et's disease: outcomes and rate of Beh\u00e7et's exacerbations in a retrospective cohort","volume":"32","author":"B\u00fcnyamin","year":"2022","journal-title":"Modern Rheumatol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.3390\/jcm10245960","article-title":"Uveitis and other ocular complications following COVID-19 vaccination","volume":"10","author":"Bolletta","year":"2021","journal-title":"J Clin Med."},{"key":"B143","doi-asserted-by":"publisher","first-page":"e248","DOI":"10.1111\/jdv.17859","article-title":"Emergence of Beh\u00e7et's disease post-SARS-CoV2-vaccination: two clinical cases in Japan","volume":"36","author":"Hashizume","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.968345\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T07:19:32Z","timestamp":1662535172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.968345\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":143,"alternative-id":["10.3389\/fmed.2022.968345"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.968345","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,7]]},"article-number":"968345"}}